Table 3. Real-life studies with AZA in... | American Society of Hematology

Table 3.

Real-life studies with AZA in AML patients

Reference	Drug	Patients, N	AML type	Prior AML therapy	Median age (range), y	Median OS, mo
42	AZA	54	Post-MPN AML (48%) or MDS	None	69.5 (37-89)	8*
43	AZA	82	Any WHO-AML subtype	57%	72 (29-87)	9
44	AZA ± VPA or ATRA	149	Any WHO-AML subtype	None	74 (31-91)	9.4
45	AZA	302	Any WHO-AML subtype	54%	73 (30-93)	9.6
46	AZA	95	Any WHO-AML subtype	None	76 (71-81)	11.3
47
Training set	AZA	110	Any WHO-AML subtype	None	75 (56-89)	8.1
Validation set	AZA	261	Any WHO-AML subtype	None	75 (31-93)	10.0
48	AZA	95	WHO-AML†	None	77 (23-93)	10.8
49	AZA	107	Post-MDS, post-MPN, and therapy-related AML	None	76.5 (71-81)	10.8
50	AZA	47	Any WHO-AML subtype	All R/R AML	63 (29-79)	9
51	AZA ± VPA or ATRA	130	Any WHO-AML subtype	All R/R AML	67 (50-80)	8.4

Reference	Drug	Patients, N	AML type	Prior AML therapy	Median age (range), y	Median OS, mo
42	AZA	54	Post-MPN AML (48%) or MDS	None	69.5 (37-89)	8*
43	AZA	82	Any WHO-AML subtype	57%	72 (29-87)	9
44	AZA ± VPA or ATRA	149	Any WHO-AML subtype	None	74 (31-91)	9.4
45	AZA	302	Any WHO-AML subtype	54%	73 (30-93)	9.6
46	AZA	95	Any WHO-AML subtype	None	76 (71-81)	11.3
47
Training set	AZA	110	Any WHO-AML subtype	None	75 (56-89)	8.1
Validation set	AZA	261	Any WHO-AML subtype	None	75 (31-93)	10.0
48	AZA	95	WHO-AML†	None	77 (23-93)	10.8
49	AZA	107	Post-MDS, post-MPN, and therapy-related AML	None	76.5 (71-81)	10.8
50	AZA	47	Any WHO-AML subtype	All R/R AML	63 (29-79)	9
51	AZA ± VPA or ATRA	130	Any WHO-AML subtype	All R/R AML	67 (50-80)	8.4

ATRA, all-trans retinoic acid; MPN, myeloproliferative neoplasm; VPA, valproic acid.

In patients fulfilling WHO-AML diagnostic criteria.

With >30% marrow blasts and WBC < 15 G/L (AZA-AML-001 Study entry criteria).